[Drug therapy of rheumatoid arthritis: where do biologics and novel synthetic disease-modifying antirheumatic drugs stand today?]
Arzneitherapie der rheumatoiden Arthritis – wo stehen Biologika und neue synthetische Basistherapeutika heute?
Antirheumatic agents
Biosimilars
Interleukin‑6 inhibitors
Janus kinase inhibitors
Tumor necrosis factor α inhibitors
Journal
Innere Medizin (Heidelberg, Germany)
ISSN: 2731-7099
Titre abrégé: Inn Med (Heidelb)
Pays: Germany
ID NLM: 9918384885306676
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
accepted:
13
06
2023
medline:
26
9
2023
pubmed:
26
7
2023
entrez:
26
7
2023
Statut:
ppublish
Résumé
Biologics and Janus kinase (JAK) inhibitors play an important role in the treatment of rheumatoid arthritis. As new therapeutic developments have emerged in recent decades, the morbidity and mortality of rheumatoid arthritis have been significantly reduced. The characterization of the structure and function of immune cell receptors has led to the development of biologics that specifically inhibit cytokines and immune cell receptors. An important therapeutic addition was the approval of JAK inhibitors, which act directly on intracellular signaling by tyrosine kinases. This article provides an overview of the current therapeutic options for rheumatoid arthritis with a special focus on indication, mechanism of action and the place in the treatment algorithm of biologics and JAK inhibitors. Biologika und Januskinase(JAK)-Inhibitoren haben einen wichtigen Stellenwert in der Therapie der rheumatoiden Arthritis. Durch die therapeutischen Weiterentwicklungen konnten in den letzten Jahrzehnten Morbidität und Mortalität der rheumatoiden Arthritis deutlich gesenkt werden. Die Charakterisierung der Struktur und Funktion der Rezeptoren von Immunzellen hat zur Entwicklung der Gruppe der Biologika geführt, die gezielt Zytokine und Rezeptoren der Immunzellen blockieren. Eine wichtige therapeutische Erweiterung war die Zulassung der JAK-Inhibitoren, die direkt auf die intrazelluläre Signaltransduktion durch Tyrosinkinasen wirken. Der vorliegende Beitrag gibt eine Übersicht über die aktuellen therapeutischen Möglichkeiten bei rheumatoider Arthritis mit besonderem Fokus auf Indikation, Wirkmechanismus und Stellenwert der Biologika und JAK-Inhibitoren.
Autres résumés
Type: Publisher
(ger)
Biologika und Januskinase(JAK)-Inhibitoren haben einen wichtigen Stellenwert in der Therapie der rheumatoiden Arthritis. Durch die therapeutischen Weiterentwicklungen konnten in den letzten Jahrzehnten Morbidität und Mortalität der rheumatoiden Arthritis deutlich gesenkt werden. Die Charakterisierung der Struktur und Funktion der Rezeptoren von Immunzellen hat zur Entwicklung der Gruppe der Biologika geführt, die gezielt Zytokine und Rezeptoren der Immunzellen blockieren. Eine wichtige therapeutische Erweiterung war die Zulassung der JAK-Inhibitoren, die direkt auf die intrazelluläre Signaltransduktion durch Tyrosinkinasen wirken. Der vorliegende Beitrag gibt eine Übersicht über die aktuellen therapeutischen Möglichkeiten bei rheumatoider Arthritis mit besonderem Fokus auf Indikation, Wirkmechanismus und Stellenwert der Biologika und JAK-Inhibitoren.
Identifiants
pubmed: 37493758
doi: 10.1007/s00108-023-01554-6
pii: 10.1007/s00108-023-01554-6
doi:
Substances chimiques
Antirheumatic Agents
0
Biological Products
0
Janus Kinase Inhibitors
0
Types de publication
English Abstract
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
1005-1012Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Listing J et al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 74(2):415–421
doi: 10.1136/annrheumdis-2013-204021
pubmed: 24291654
Barnabe C, Martin BJ, Ghali WA (2011) Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 63(4):522–529
doi: 10.1002/acr.20371
pubmed: 20957658
ter Wee MM et al (2012) The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. Ann Rheum Dis 71(2):161–171
doi: 10.1136/ard.2011.154583
pubmed: 21998122
O’Shea JJ, Laurence A, McInnes IB (2013) Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol 9(3):173–182
doi: 10.1038/nrrheum.2013.7
pubmed: 23419429
pmcid: 4169143
Fiehn C (2022) Biologikatherapie von rheumatoider Arthritis und Spondyloarthritiden. Internist 63(2):135–142
doi: 10.1007/s00108-021-01248-x
pubmed: 35029702
Burmester GR, Pope JE (2017) Novel treatment strategies in rheumatoid arthritis. Lancet 389(10086):2338–2348
doi: 10.1016/S0140-6736(17)31491-5
pubmed: 28612748
Fiehn C et al (2018) S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs. Z Rheumatol 77(2):35–53
doi: 10.1007/s00393-018-0481-y
pubmed: 29968101
Combe B et al (2017) 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 76(6):948–959
doi: 10.1136/annrheumdis-2016-210602
pubmed: 27979873
Aringer M et al (2019) 2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78(9):1151–1159
doi: 10.1136/annrheumdis-2018-214819
pubmed: 31383717
Golicki D et al (2012) Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials. Pol Arch Med Wewn 122(1):22–32
pubmed: 22353705
Smolen JS et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European leflunomide study group. Lancet 353(9149):259–266
doi: 10.1016/S0140-6736(98)09403-3
pubmed: 9929017
Verschueren P et al (2017) Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1‑year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis 76(3):511–520
doi: 10.1136/annrheumdis-2016-209212
pubmed: 27432356
Goekoop-Ruiterman YP et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146(6):406–415
doi: 10.7326/0003-4819-146-6-200703200-00005
pubmed: 17371885
Kiely P et al (2011) Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity—the early RA network (ERAN). Rheumatology 50(5):926–931
doi: 10.1093/rheumatology/keq406
pubmed: 21169343
Blüml S (2020) Biologicals and small molecules for rheumatoid arthritis. Z Rheumatol 79(3):223–231
doi: 10.1007/s00393-020-00766-7
pubmed: 32179964
Aaltonen KJ et al (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 7(1):e30275
doi: 10.1371/journal.pone.0030275
pubmed: 22272322
pmcid: 3260264
Mariette X et al (2018) Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 77(2):228–233
doi: 10.1136/annrheumdis-2017-212196
pubmed: 29030361
Burmester GR et al (2015) Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 74(6):1037–1044
doi: 10.1136/annrheumdis-2013-204769
pubmed: 24550168
Witte T (2015) Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint? Clin Rheumatol 34(4):629–634
doi: 10.1007/s10067-015-2861-x
pubmed: 25604317
pmcid: 4365184
Gabay C et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381(9877):1541–1550
doi: 10.1016/S0140-6736(13)60250-0
pubmed: 23515142
Jones G et al (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69(1):88–96
doi: 10.1136/ard.2008.105197
pubmed: 19297346
Lee HK, Iwasaki A (2007) Innate control of adaptive immunity: dendritic cells and beyond. Semin Immunol 19(1):48–55
doi: 10.1016/j.smim.2006.12.001
pubmed: 17276695
Sokolove J et al (2016) Impact of baseline anti-cyclic citrullinated peptide‑2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2‑year results from the AMPLE trial. Ann Rheum Dis 75(4):709–714
doi: 10.1136/annrheumdis-2015-207942
pubmed: 26359449
Blüml S et al (2013) B‑cell targeted therapeutics in clinical development. Arthritis Res Ther 15(1):S4
doi: 10.1186/ar3906
pubmed: 23566679
pmcid: 3624127
Isaacs JD et al (2013) Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 72(3):329–336
doi: 10.1136/annrheumdis-2011-201117
pubmed: 22689315
Md Yusof MY et al (2019) Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 71(11):1812–1823
doi: 10.1002/art.40937
pubmed: 31131994
Yeoh SA et al (2022) Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 global rheumatology alliance physician-reported registry. RMD Open 8(2):e2508. https://doi.org/10.1136/rmdopen-2022-002508
doi: 10.1136/rmdopen-2022-002508
pubmed: 36100295
FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors (2021) Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 80(4):527–538
doi: 10.1136/annrheumdis-2020-218310
Grieshaber-Bouyer R, Lorenz HM (2020) Biosimilars: opportunities and risks. Internist (Berl) 61(5):522–529
doi: 10.1007/s00108-020-00784-2
pubmed: 32333085
Schneider CK (2013) Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 72(3):315–318
doi: 10.1136/annrheumdis-2012-202941
pubmed: 23390018
Gadina M et al (2019) Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology 58(1):i4–i16
doi: 10.1093/rheumatology/key432
pubmed: 30806710
pmcid: 6657570
Fleischmann R et al (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64(3):617–629
doi: 10.1002/art.33383
pubmed: 21952978
Krause A, Krüger K (2023) Empfehlungen der Deutschen Gesellschaft für Rheumatologie: Januskinase-Inhibitoren (JAKi) – wie ist mit den neuenVerordnungseinschränkungen umzugehen?
Ytterberg SR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316–326
doi: 10.1056/NEJMoa2109927
pubmed: 35081280
Charles-Schoeman C et al (2023) Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance. Ann Rheum Dis 82(1):119–129
doi: 10.1136/ard-2022-222259
pubmed: 36137735
Meissner Y et al (2022) OP0135 RISK OF CARDIOVASCULAR EVENTS UNDER JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: OBSERVATIONAL DATA FROM THE GERMAN RABBIT REGISTER. Ann Rheum Dis 81(1):86–87
Wagner N et al (2019) Impfen bei Immundefizienz. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 62(4):494–515
doi: 10.1007/s00103-019-02905-1
pubmed: 30899964
Winthrop KL (2017) The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13(4):234–243
doi: 10.1038/nrrheum.2017.23
pubmed: 28250461